Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs ACTAVIS (US) - Comparison Results

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 GLENMARK PHARMA   ACTAVIS
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-23
ACTAVIS
Dec-18
GLENMARK PHARMA/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs48716,126-   
Low Rs34910,818-   
Sales per share (Unadj.) Rs460.43,955.8-  
Earnings per share (Unadj.) Rs13.4-1,274.2-  
Cash flow per share (Unadj.) Rs35.0416.9-  
Dividends per share (Unadj.) Rs2.500-  
Avg Dividend yield %0.60-  
Book value per share (Unadj.) Rs335.116,315.7-  
Shares outstanding (eoy) m282.17332.60-   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x0.93.4 26.7%   
Avg P/E ratio x31.3-10.6 -295.6%  
P/CF ratio (eoy) x11.932.3 36.9%  
Price / Book Value ratio x1.20.8 151.1%  
Dividend payout %18.70-   
Avg Mkt Cap Rs m117,9534,480,758 2.6%   
No. of employees `000NA16.9 0.0%   
Total wages/salary Rs m27,8100-   
Avg. sales/employee Rs Th077,851.4-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th0-25,076.0-  
INCOME DATA
Net Sales Rs m129,9011,315,689 9.9%  
Other income Rs m3,16825,160 12.6%   
Total revenues Rs m133,0691,340,849 9.9%   
Gross profit Rs m15,12534,478 43.9%  
Depreciation Rs m6,113562,428 1.1%   
Interest Rs m3,49675,923 4.6%   
Profit before tax Rs m8,685-578,713 -1.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0147,595 0.0%   
Tax Rs m4,911-7,334 -67.0%   
Profit after tax Rs m3,774-423,784 -0.9%  
Gross profit margin %11.62.6 444.3%  
Effective tax rate %56.51.3 4,461.8%   
Net profit margin %2.9-32.2 -9.0%  
BALANCE SHEET DATA
Current assets Rs m98,737539,627 18.3%   
Current liabilities Rs m50,455477,372 10.6%   
Net working cap to sales %37.24.7 785.5%  
Current ratio x2.01.1 173.1%  
Inventory Days Days720 34.2%  
Debtors Days Days11566 173.7%  
Net fixed assets Rs m76,920148,929 51.6%   
Share capital Rs m2820-   
"Free" reserves Rs m94,2810-   
Net worth Rs m94,5635,426,601 1.7%   
Long term debt Rs m38,5211,910,903 2.0%   
Total assets Rs m175,6588,483,012 2.1%  
Interest coverage x3.5-6.6 -52.6%   
Debt to equity ratio x0.40.4 115.7%  
Sales to assets ratio x0.70.2 476.8%   
Return on assets %4.1-4.1 -100.9%  
Return on equity %4.0-7.8 -51.1%  
Return on capital %9.2-4.8 -189.1%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m33,7510-   
CASH FLOW
From Operations Rs m6,254470,046 1.3%  
From Investments Rs m-5,285258,229 -2.0%  
From Financial Activity Rs m-775-806,740 0.1%  
Net Cashflow Rs m325-78,073 -0.4%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 83.34 Rs / USD

Compare GLENMARK PHARMA With: ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare GLENMARK PHARMA With: KIMIA BIOSCIENCES  DESH RAKSHAK  AVON ORGANIC  HIKAL.  NECTAR LIFESCIENCE  



Today's Market

Sensex Today Rallies 639 Points | Suzlon Energy Surges 5%, Grasim Industries 4% | 3 Reasons Why Indian Share Market is Rising Sensex Today Rallies 639 Points | Suzlon Energy Surges 5%, Grasim Industries 4% | 3 Reasons Why Indian Share Market is Rising(Closing)

After opening the day on positive note, Indian share markets gained the momentum as the session progressed and ended on firm footing.